Compare MAMA & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | ZURA |
|---|---|---|
| Founded | 2010 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.2M | 435.0M |
| IPO Year | 2011 | N/A |
| Metric | MAMA | ZURA |
|---|---|---|
| Price | $16.49 | $6.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $16.80 | $11.78 |
| AVG Volume (30 Days) | 450.2K | ★ 461.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $95,420,129.00 | N/A |
| Revenue This Year | $41.59 | N/A |
| Revenue Next Year | $33.43 | N/A |
| P/E Ratio | $210.75 | ★ N/A |
| Revenue Growth | ★ 95.54 | N/A |
| 52 Week Low | $6.05 | $0.99 |
| 52 Week High | $17.85 | $7.25 |
| Indicator | MAMA | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 50.67 |
| Support Level | $15.36 | $5.62 |
| Resistance Level | $17.85 | $6.99 |
| Average True Range (ATR) | 0.75 | 0.50 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 53.01 | 30.91 |
Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.